Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of Acentus, a national medical ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Henry Schein (HSIC – Research Report) yesterday and set a price target ...

Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).

Fintel reports that on January 6, 2025, B of A Securities upgraded their outlook for Henry Schein (NasdaqGS:HSIC) from ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...

The projected fair value for Henry Schein is US$67.04 based on 2 Stage Free Cash Flow to Equity With US$70.70 share price, Henry Schein appears to be trading close to its estimated fair value ...

BofA sees 2025 challenges for healthcare tech and distributors but upgrades Cardinal Health and Henry Schein, highlighting ...

Shares of Henry Schein Inc. HSIC shed 1.96% to $69.67 Friday, on what proved to be an all-around dismal trading session for ...

Below is Validea's guru fundamental report for HENRY SCHEIN, INC. (HSIC). Of the 22 guru strategies we follow, HSIC rates highest using our Shareholder Yield Investor model based on the published ...

The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...